* Gilead Sciences Inc reported a quarterly adjusted loss of $1.32 per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of $1.37. The mean expectation of twenty three analysts for the quarter was for a loss of $1.49 per share. Wall Street expected results to range from $-1.86 to $-1.14 per share.
* Revenue rose 5.3% to $6.69 billion from a year ago; analysts expected $6.34 billion.
* Gilead Sciences Inc's reported EPS for the quarter was a loss of $3.34.
* The company reported a quarterly loss of $4.17 billion.
* Gilead Sciences Inc shares had fallen by 8.4% this quarter and lost 17.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 187.1% in the last three months.
* In the last 30 days, thirteen analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 19 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Gilead Sciences Inc is $80.00 This summary was machine generated from LSEG data April 25 at 11:08 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.49 -1.32 Beat
Dec. 31 2023 1.76 1.72 Missed
Sep. 30 2023 1.92 2.29 Beat
Jun. 30 2023 1.64 1.66 Beat
Comments